Evidence mapPaperPMID 41771997Full record

Trial reportScientific reports2026

Protocol of the randomized double blind sham controlled AddVNS study of transcutaneous vagus nerve stimulation mechanisms in depression.

Evangelos Kokolakis, Iven-Alex von Mücke-Heim, Julius C Pape, Norma C Grandi, Angelika Erhardt, Philipp G Sämann, Victor Spoormaker, Nadine Gogolla, Elisabeth B Binder, Peter Falkai

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Evangelos Kokolakis *Department Clinical Translation, Max Planck Institute of Psychiatry (MPIP), Munich, Germany.
Iven-Alex von Mücke-Heim *Department Clinical Translation, Max Planck Institute of Psychiatry (MPIP), Munich, Germany. iven_muecke-heim@psych.mpg.de.
Julius C PapeDepartment Genes and Environment, MPIP, Munich, Germany.
Norma C GrandiDepartment Clinical Translation, Max Planck Institute of Psychiatry (MPIP), Munich, Germany.
Angelika ErhardtPsychiatry Department, Clinical Anxiety Research, University of Würzburg, Würzburg, Germany.
Philipp G SämannNeuroimaging Core Unit, MPIP, Munich, Germany.
Victor SpoormakerDepartment Genes and Environment, MPIP, Munich, Germany.
Nadine GogollaDepartment Emotion Research, MPIP, Munich, Germany.
Elisabeth B BinderDepartment Genes and Environment, MPIP, Munich, Germany.
Peter FalkaiDepartment Clinical Translation, Max Planck Institute of Psychiatry (MPIP), Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression is among the most prevalent mental disorders worldwide, carrying one of the highest burden of disease among all mental disorders. While invasive vagus nerve stimulation has been approved for treatment-resistant depression for decades, its clinical use is limited by surgical risks and heterogeneous clinical efficacy. Transcutaneous auricular VNS (tVNS) may offer a non-invasive alternative, but to date it remains experimental due to limited high-quality evidence, unclear biological mechanisms of action, and rudimentary knowledge on optimal stimulation parameters. To address these gaps, we initiated the AddVNS study. The AddVNS study (Add-on tVNS in depression) is a monocentric, exploratory, prospective, randomized, double-blind, sham-controlled interventional trial conducted at the Max Planck Institute of Psychiatry's research hospital. Adult patients with a depressive episode (ICD-10: F31-33) were assigned to receive active or sham transcutaneous vagus nerve stimulation (tVNS) in addition to treatment-as-usual (TAU) over a six-week period. Stimulation is administered three times daily (30 to 60 min each), five days per week. A deep phenotyping strategy is applied, including repeated psychophysiological measures (e.g., pupillometry, ECG, photoplethysmography, electrogastrogram) and neuroimaging (structural and functional MRI) at baseline and post-intervention, continuous actigraphy, repeated blood and stool sample acquisition (pre-, mid-, and post-intervention) for multiomic investigation, comprehensive neuropsychology including self-rated personality assessment, and closely monitored clinical evaluations. The patient-reported outcomes are collected weekly, the clinician-rated scales pre-, mid-, and post-intervention. In addition, follow-up self-ratings are obtained at 6 and 12 weeks post-tVNS. The main objective of AddVNS is to improve our understanding of the biological effects elicited by tVNS in depression. By combining rigorous methodology with an extensive and longitudinal multimodal approach, AddVNS represents the most comprehensive investigation of tVNS effects and markers in depression to date. We believe it to significantly advance our mechanistic understanding and subsequently clinical translation of this promising intervention.

Indexed as

DepressionTranscutaneous Electric Nerve StimulationVagus Nerve StimulationAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedProspective StudiesTreatment Outcome

Identifiers

PMID41771997
PMCPMC12960843

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.